日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial

吡啶斯的明可降低重症 SARS-CoV-2 感染患者的死亡率：一项 2/3 期随机对照试验

期刊:Molecular Medicine
影响因子:6.4
doi:10.1186/s10020-022-00553-x
Fragoso-Saavedra, Sergio; Núñez, Isaac; Audelo-Cruz, Belem M; Arias-Martínez, Sarahi; Manzur-Sandoval, Daniel; Quintero-Villegas, Alejandro; Benjamín García-González, H; Carbajal-Morelos, Sergio L; PoncedeLeón-Rosales, Sergio; Gotés-Palazuelos, José; Maza-Larrea, José A; Rosales-de la Rosa, J Javier; Diaz-Rivera, Dafne; Luna-García, Edgar; Piten-Isidro, Elvira; Del Río-Estrada, Perla M; Fragoso-Saavedra, Mario; Caro-Vega, Yanink; Batina, Isabella; Islas-Weinstein, León; Iruegas-Nunez, David A; Calva, Juan J; Belaunzarán-Zamudio, Pablo F; Sierra-Madero, Juan; Crispín, José C; Valdés-Ferrer, Sergio Iván
炎症/感染
SARS-CoV-2
发表日期：2022
文献求助 收藏

A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

一项平行组、多中心、随机、双盲、安慰剂对照的 II/III 期临床试验，旨在检验低剂量溴吡斯的明降低重症 SARS-CoV-2 感染成人患者死亡率或有创机械通气需求的疗效：重症 COVID-19 患者溴吡斯的明 (PISCO) 试验方案

期刊:BMC Infectious Diseases
影响因子:3
doi:10.1186/s12879-020-05485-7
Fragoso-Saavedra, Sergio; Iruegas-Nunez, David A; Quintero-Villegas, Alejandro; García-González, H Benjamín; Nuñez, Isaac; Carbajal-Morelos, Sergio L; Audelo-Cruz, Belem M; Arias-Martínez, Sarahi; Caro-Vega, Yanink; Calva, Juan José; Luqueño-Martínez, Verónica; González-Duarte, Alejandra; Crabtree-Ramírez, Brenda; Crispín, José C; Sierra-Madero, Juan; Belaunzarán-Zamudio, Pablo F; Valdés-Ferrer, Sergio I
炎症/感染
SARS-CoV-2
发表日期：2020
文献求助 收藏